2025, Vol. 7, Issue 2, Part F
Rituximab in neurological disease: Principles, evidence and practice in Amara city at Alsader teaching hospital in Maysan
Author(s): Abbas Kinbar Kuser
Abstract: Rituximab is a popular monoclonal antibody that kills B cells. There are no treatment recommendations and it is not approved for use in treating neurological disorders. However, it is an appealing substitute for traditional immunomodulatory drugs as a swiftly acting, targeted therapy with mounting evidence of efficacy and tolerance in numerous neuroinflammatory conditions. The goal of this hands-on review is to clarify the fundamental ideas behind therapeutic monoclonal antibody B-cell depletion. We discuss the scientific support for the use of rituximab in neurological illnesses as well as dose, monitoring, safety, treatment failure, and its application in unique situations such concurrent viral hepatitis, pregnancy, and breastfeeding. We offer a patient information booklet, administration guide, and checklist that can be customized for local use. Lastly, we assess the security.
DOI: 10.22271/27081494.2025.v7.i2f.246Pages: 384-393 | Views: 228 | Downloads: 48Download Full Article: Click Here
How to cite this article:
Abbas Kinbar Kuser.
Rituximab in neurological disease: Principles, evidence and practice in Amara city at Alsader teaching hospital in Maysan. Int J Case Rep Surg 2025;7(2):384-393. DOI:
10.22271/27081494.2025.v7.i2f.246
